Five Prime Therapeutics Inc represents a strong commitment to advancing innovative therapies in the field of biotechnology. With a focus on groundbreaking research and development, the company strives to improve the lives of patients and deliver transformative medicines. Five Prime Therapeutics Inc's corporate philosophy encompasses a collaborative approach, leveraging cutting-edge technologies and scientific expertise to tackle unmet medical needs. By fostering a culture of exploration, innovation, and integrity, the company aims to optimize patient outcomes and create long-term value for its stakeholders.

Five Prime Therapeutics Inc is primarily present in the United States.

Five Prime Therapeutics Inc has achieved several significant milestones. Firstly, it successfully advanced its lead drug candidate, bemarituzumab, into Phase 3 clinical trials. This antibody targets FGFR2b, a receptor found in various cancers, including gastric and gastroesophageal junction cancers. The company has also entered into collaborations with renowned organizations, such as Bristol Myers Squibb, for the development of innovative therapies. Additionally, Five Prime Therapeutics Inc received Fast Track designation from the FDA for bemarituzumab, which accelerates the regulatory review process. These achievements highlight the company's dedication to advancing novel treatments for patients in need.

Five Prime Therapeutics Inc. is a biotechnology company specializing in the discovery and development of innovative protein-based therapeutics. Founded in 2002, Five Prime Therapeutics has a rich history of pioneering research and collaborations with leading academic institutions and pharmaceutical companies. The company focuses on identifying and targeting novel pathways to enhance the effectiveness of cancer immunotherapies, with a particular emphasis on areas such as immune-oncology and precision medicine. With a strong portfolio of potential drug candidates in various stages of development, Five Prime Therapeutics is committed to advancing the field of biotechnology to address unmet medical needs and improve patient outcomes.

The main competitors of Five Prime Therapeutics Inc in the market are companies such as Amgen, Inc., Merck & Co., Inc., and Bristol-Myers Squibb Company. These companies also operate in the pharmaceutical and biotechnology industry and compete with Five Prime Therapeutics Inc in areas such as drug development, research, and commercialization.

Five Prime Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Five Prime Therapeutics Inc is focused on developing innovative protein therapeutics to target a range of diseases. The company utilizes its proprietary library of human extracellular proteins to discover and develop potential therapeutics. With a focus on immuno-oncology, Five Prime Therapeutics aims to improve outcomes for patients through the development of targeted and personalized therapies. By leveraging their expertise in protein science and drug discovery, the company aims to address unmet medical needs and deliver value to patients, healthcare providers, and shareholders.

Five Prime Therapeutics P/E suhe on −15,03.

Five Prime Therapeutics KUV on 155,36.

AlleAktien kvaliteediskoor ettevõttele Five Prime Therapeutics on 2/10.

oodatud Five Prime Therapeutics käive on 9,01 mln. USD.

oodatud Five Prime Therapeutics kasum on −93,14 mln. USD.

Five Prime Therapeutics Inc is a biopharmaceutical company that focuses on the discovery and development of targeted protein therapies for the treatment of serious diseases. The company uses its proprietary protein library to identify and validate new targets and therapies. One of Five Prime's key products is FPA150, a monoclonal antibody targeting the TGF-beta receptor 2 (TGFBR2) that can be used for cancer treatment. The company is also working on the development of immune-based cancer therapies that activate T-cells. Another important division of Five Prime is drug development. The company collaborates closely with partners in the pharmaceutical and biotechnology industry to address various disease areas, including cancer, inflammatory diseases, and autoimmunity. Partners include Bristol-Myers Squibb, GlaxoSmithKline, and UCB Pharma. Additionally, the company has established partnerships with other companies such as Bio-Techne Corporation in the field of cancer diagnostics. Five Prime also has its own research department that constantly works on discovering new targets and therapies. The company utilizes cutting-edge technologies such as CRISPR-Cas9 genome editing and RNA sequencing. Five Prime's business model is based on utilizing its proprietary technology and protein library to identify and develop new targets and therapies. These products are then marketed either through partnerships with other companies or through its own drug development. The company finances its research and development activities through investments from venture capitalists, revenue from partnerships and licensing fees, as well as revenue from the sale of its products. Overall, Five Prime Therapeutics has built a promising business model based on its proprietary technology and protein library. The company is well positioned to continue developing innovative therapeutic approaches and financing its research and development through partnerships and investments.

Five Prime Therapeutics maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Five Prime Therapeutics jaoks arvutada või ettevõte ei maksa dividende välja.

Five Prime Therapeutics ISIN on US33830X1046.

Five Prime Therapeutics WKN on A1W5T9.

Five Prime Therapeutics tähis on FPRX.

Viimase 12 kuu jooksul maksis Five Prime Therapeutics dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Five Prime Therapeutics tõenäoliselt dividendi summas 0 USD.

Five Prime Therapeutics praegune dividenditootlus on .

Five Prime Therapeutics maksab kvartaalset dividendi. See makstakse välja kuudel .

Five Prime Therapeutics maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

Five Prime Therapeutics on liigitatud sektorisse 'Tervis'.

Viimase Five Prime Therapeutics dividendide saamiseks 12.7.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 12.7.2024.

Viimane dividendimakse toimus 12.7.2024.

Aastal 2023 maksis Five Prime Therapeutics 0 USD dividende.

Five Prime Therapeutics dividendid makstakse välja USD.